Pacific Biosciences Of California (PACB) Net Cash Flow Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Pacific Biosciences Of California | 481.66 Mn | 205.70 Mn | 12.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.97% |
| Dec 31, 2025 | -11.91% |
| Sep 30, 2025 | -42.15% |
| Jun 30, 2025 | 30.92% |
| Mar 31, 2025 | -39.67% |
| Dec 31, 2024 | -45.59% |
| Sep 30, 2024 | -58.23% |
| Jun 30, 2024 | 36.20% |
| Mar 31, 2024 | -48.96% |
| Dec 31, 2023 | -60.66% |
| Sep 30, 2023 | 63.69% |
| Jun 30, 2023 | -127.12% |
| Mar 31, 2023 | 26.28% |
| Dec 31, 2022 | 33.19% |
| Sep 30, 2022 | 10.63% |
| Jun 30, 2022 | -78.38% |
| Mar 31, 2022 | -35.69% |
| Dec 31, 2021 | 51.06% |
| Jun 30, 2021 | -152.59% |
| Mar 31, 2021 | 130.31% |
| Dec 31, 2020 | 15.36% |
| Sep 30, 2020 | 82.24% |
| Jun 30, 2020 | -43.07% |
| Mar 31, 2020 | 52.88% |
| Dec 31, 2019 | -39.75% |
| Sep 30, 2019 | -17.68% |
| Jun 30, 2019 | 8.57% |
| Mar 31, 2019 | 5.38% |
| Dec 31, 2018 | 12.93% |
| Sep 30, 2018 | -8.92% |
| Jun 30, 2018 | 27.77% |
| Mar 31, 2018 | 6.62% |
| Dec 31, 2017 | -21.74% |
| Sep 30, 2017 | -58.18% |
| Jun 30, 2017 | 18.44% |
| Mar 31, 2017 | 46.25% |
| Dec 31, 2016 | -46.25% |
| Sep 30, 2016 | -21.49% |
| Jun 30, 2016 | 16.61% |
| Mar 31, 2016 | 26.47% |
| Dec 31, 2015 | -40.34% |
| Sep 30, 2015 | 15.40% |